abrdn Life Sciences Investors (NYSE:HQL) Sees Large Decrease in Short Interest

abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 18,442 shares, a decrease of 70.6% from the July 15th total of 62,733 shares. Based on an average daily trading volume, of 177,512 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.1% of the company’s shares are sold short.

abrdn Life Sciences Investors Price Performance

HQL traded up $0.01 during trading hours on Friday, reaching $21.16. 111,211 shares of the company’s stock traded hands, compared to its average volume of 168,577. The firm has a 50-day moving average price of $19.36 and a 200 day moving average price of $17.89. abrdn Life Sciences Investors has a 52-week low of $13.57 and a 52-week high of $21.42.

abrdn Life Sciences Investors Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th will be issued a $0.62 dividend. The ex-dividend date is Monday, August 24th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 11.7%.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Large investors have recently added to or reduced their stakes in the stock. KPP Advisory Services LLC lifted its holdings in shares of abrdn Life Sciences Investors by 2.7% in the 2nd quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock worth $505,000 after buying an additional 660 shares during the period. 180 Wealth Advisors LLC lifted its stake in abrdn Life Sciences Investors by 2.2% in the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock worth $3,058,000 after acquiring an additional 3,271 shares during the period. NewEdge Advisors LLC lifted its stake in abrdn Life Sciences Investors by 17.6% in the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock worth $387,000 after acquiring an additional 3,562 shares during the period. WNY Asset Management LLC bought a new position in abrdn Life Sciences Investors during the 1st quarter worth about $239,000. Finally, Bank of America Corp DE grew its holdings in abrdn Life Sciences Investors by 8.6% during the 1st quarter. Bank of America Corp DE now owns 115,585 shares of the company’s stock worth $1,881,000 after acquiring an additional 9,145 shares in the last quarter. 32.21% of the stock is owned by hedge funds and other institutional investors.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.